98%
921
2 minutes
20
Introduction: This study aimed to explore the value of diffusion tensor imaging (DTI)- based radiomics in the early diagnosis of Alzheimer's disease (AD) and predicting the progression of mild cognitive impairment (MCI) to AD.
Methods: A cohort of 186 patients with MCI was obtained from the publicly accessible Alzheimer's. Disease Neuroimaging Initiative (ADNI) database, and 49 of these individuals developed AD over a 5-year observation period. The subjects were divided into a training set and a test set in a ratio of 7 to 3. Radiomic features were extracted from the corpus callosum within the DTI post-processed images. The Least Absolute Shrinkage and Selection Operator (LASSO) logistic regression algorithm was employed to develop radiomic signatures. The performance of the radiomic signature was assessed using receiver operating characteristic (ROC) analysis and decision curve analysis (DCA).
Results: In the training set, 35 patients were converted, and in the test set, 14 patients were converted. Among all the patients, notable differences were observed in age, CDR-SB, ADAS, MMSE, FAQ, and MOCA between the stable group and the transformed group (p < 0.05). In the test set, the AUCs of the radiomics signatures constructed based on fractional anisotropy, axial diffusivity, mean diffusivity, and radial diffusivity were 0.824, 0.852, 0.833, and 0.862, respectively. The AUC of the clinical model was 0.868, and that of the combined model was 0.936. DCA demonstrated that the combined model had the best performance.
Discussion Conclusion: The combined radiomics and clinical model, utilizing DTI data, can relatively accurately forecast which patients with MCI are likely to progress to AD. This approach offers potential for early AD prevention in MCI patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2174/0115672050390986250801005607 | DOI Listing |
Stroke
September 2025
Department of Neurology, Yale School of Medicine, New Haven, CT (L.H.S.).
Preclinical stroke research faces a critical translational gap, with animal studies failing to reliably predict clinical efficacy. To address this, the field is moving toward rigorous, multicenter preclinical randomized controlled trials (mpRCTs) that mimic phase 3 clinical trials in several key components. This collective statement, derived from experts involved in mpRCTs, outlines considerations for designing and executing such trials.
View Article and Find Full Text PDFACS Sens
September 2025
Institute of Applied Mechanics, National Taiwan University, Taipei 106, Taiwan.
In recent AI-driven disease diagnosis, the success of models has depended mainly on extensive data sets and advanced algorithms. However, creating traditional data sets for rare or emerging diseases presents significant challenges. To address this issue, this study introduces a direct-self-attention Wasserstein generative adversarial network (DSAWGAN) designed to improve diagnostic capabilities in infectious diseases with limited data availability.
View Article and Find Full Text PDFGeroscience
September 2025
Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
This study aims to investigate the predictive value of combined phenotypic age and phenotypic age acceleration (PhenoAgeAccel) for benign prostatic hyperplasia (BPH) and develop a machine learning-based risk prediction model to inform precision prevention and clinical management strategies. The study analyzed data from 784 male participants in the US National Health and Nutrition Examination Survey (NHANES, 2001-2008). Phenotypic age was derived from chronological age and nine serum biomarkers.
View Article and Find Full Text PDFJ Cancer Res Clin Oncol
September 2025
Department of Radiology, Guizhou Provincial People's Hospital, No. 83 East Zhongshan Road, Guiyang, 550002, Guizhou, China.
Purpose: Targeted therapy with lenvatinib is a preferred option for advanced hepatocellular carcinoma, however, predicting its efficacy remains challenging. This study aimed to build a nomogram integrating clinicoradiological indicators and radiomics features to predict the response to lenvatinib in patients with hepatocellular carcinoma.
Methods: This study included 211 patients with hepatocellular carcinoma from two centers, who were allocated into the training (107 patients), internal test (46 patients) and external test set(58 patients).
BMJ Open
September 2025
Department of Gastroenterology, Hepatology, Infectious Diseases and Intoxication, University Hospital Heidelberg, Heidelberg, Germany.
Introduction: Combined vascular endothelial growth factor/programmed death-ligand 1 blockade through atezolizumab/bevacizumab (A/B) is the current standard of care in advanced hepatocellular carcinoma (HCC). A/B substantially improved objective response rates compared with tyrosine kinase inhibitor sorafenib; however, a majority of patients will still not respond to A/B. Strong scientific rationale and emerging clinical data suggest that faecal microbiota transfer (FMT) may improve antitumour immune response on PD-(L)1 blockade.
View Article and Find Full Text PDF